(EL) EssilorLuxottica S. A. - PA
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: PA (France) | Market Cap: 79.870m EUR | Total Return: 9.2% in 12m
Avg Turnover: 121M
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
EssilorLuxottica S.A. (EL) is a Paris-headquartered company, founded in 1849 and reorganized under its current name in October 2018 following the combination of lens maker Essilor and eyewear manufacturer Luxottica. The group designs, manufactures, and globally distributes ophthalmic lenses, frames, sunglasses, contact lenses, and a wide range of optician instruments and diagnostic equipment, operating across North America, Europe, the Middle East and Africa, Latin America, and Asia-Pacific.
Its portfolio spans both healthcare-oriented and consumer-facing eyewear brands, including Varilux, Crizal, Stellest, and Transitions on the lens side, and Ray-Ban, Oakley, Persol, Oliver Peoples, and Vogue Eyewear in fashion frames. Through brands such as Satisloh and the SPECTRALIS imaging platform, it also supplies eye-care professionals with refraction, edging, finishing, and diagnostic hardware, making the business one of the few players that is vertically integrated from lens and frame manufacturing through to retail distribution.
Distribution reaches independent opticians, third-party e-commerce platforms, and large retail chains, alongside the companys own brick-and-mortar stores and online channels. The eyewear industry is unusual in straddling health care (corrective lenses, diagnostics, optical instruments) and consumer discretionary (fashion sunglasses, branded frames), which is reflected in EssilorLuxotticas positioning as both a health care equipment supplier and a major branded eyewear retailer.
- Ray-Ban Meta smart glasses accelerate wearables revenue growth
- Retail vertical integration through LensCrafters and Sunglass Hut boosts operating margins
- Europe and China consumer softness pressures reported revenue growth
| Net Income: 2.31b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.68 > 1.0 |
| NWC/Revenue: -0.51% < 20% (prev -1.96%; Δ 1.45% < -1%) |
| CFO/TA 0.08 > 3% & CFO 5.29b > Net Income 2.31b |
| Net Debt (14.4b) to EBITDA (6.54b): 2.20 < 3 |
| Current Ratio: 0.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (469.3m) vs 12m ago 3.56% < -2% |
| Gross Margin: 60.56% > 18% (prev 62.52%; Δ -1.97% > 0.5%) |
| Asset Turnover: 44.46% > 50% (prev 41.25%; Δ 3.21% > 0%) |
| Interest Coverage Ratio: 10.92 > 6 (EBIT TTM 3.43b / Interest Expense TTM 314.0m) |
| A: -0.00 (Total Current Assets 12.0b - Total Current Liabilities 12.2b) / Total Assets 63.9b |
| B: 0.25 (Retained Earnings 16.1b / Total Assets 63.9b) |
| C: 0.05 (EBIT TTM 3.43b / Avg Total Assets 64.1b) |
| D: 1.59 (Book Value of Equity 38.9b / Total Liabilities 24.4b) |
| Altman-Z'' = 2.84 = A |
| DSRI: 1.07 (Receivables 3.77b/3.26b, Revenue 28.5b/26.5b) |
| GMI: 1.03 (GM 62.52% / 60.56%) |
| AQI: 0.96 (AQ_t 0.67 / AQ_t-1 0.70) |
| SGI: 1.07 (Revenue 28.5b / 26.5b) |
| TATA: -0.05 (NI 2.31b - CFO 5.29b) / TA 63.9b) |
| Beneish M = -2.91 (Cap -4..+1) = A |
As of June 22, 2026, the stock is trading at EUR 173.55 with a total of 1,398,789 shares traded.
Over the past week, the price has changed by -3.65%,
over one month by +7.89%,
over three months by +7.38% and
over the past year by +9.17%.
EssilorLuxottica S. A. has no consensus analysts rating.
P/E Trailing = 34.8494
P/E Forward = 22.6757
P/S = 2.8033
P/B = 2.0538
P/EG = 1.6124
Revenue TTM = 28.5b EUR
EBIT TTM = 3.43b EUR
EBITDA TTM = 6.54b EUR
Long Term Debt = 6.81b EUR (from longTermDebt, last quarter)
Short Term Debt = 3.68b EUR (from shortTermDebt, last quarter)
Debt = 18.0b EUR (from shortLongTermDebtTotal, last quarter) + Leases 3.56b
Net Debt = 14.4b EUR (calculated: Debt 18.0b - CCE 3.54b)
Enterprise Value = 94.3b EUR (79.9b + Debt 18.0b - CCE 3.54b)
Interest Coverage Ratio = 10.92 (Ebit TTM 3.43b / Interest Expense TTM 314.0m)
EV/FCF = 25.04x (Enterprise Value 94.3b / FCF TTM 3.77b)
FCF Yield = 3.99% (FCF TTM 3.77b / Enterprise Value 94.3b)
FCF Margin = 13.22% (FCF TTM 3.77b / Revenue TTM 28.5b)
Net Margin = 8.13% (Net Income TTM 2.31b / Revenue TTM 28.5b)
Gross Margin = 60.56% ((Revenue TTM 28.5b - Cost of Revenue TTM 11.2b) / Revenue TTM)
Gross Margin QoQ = 58.15% (prev 63.05%)
Tobins Q-Ratio = 1.48 (Enterprise Value 94.3b / Total Assets 63.9b)
Interest Expense / Debt = 1.75% (Interest Expense 314.0m / Debt 18.0b)
Taxrate = 23.54% (752.0m / 3.19b)
NOPAT = 2.62b (EBIT 3.43b * (1 - 23.54%))
Current Ratio = 0.99 (Total Current Assets 12.0b / Total Current Liabilities 12.2b)
Debt / Equity = 0.46 (Debt 18.0b / totalStockholderEquity, last quarter 38.9b)
Debt / EBITDA = 2.20 (Net Debt 14.4b / EBITDA 6.54b)
Debt / FCF = 3.83 (Net Debt 14.4b / FCF TTM 3.77b)
Total Stockholder Equity = 39.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.61% (Net Income 2.31b / Total Assets 63.9b)
RoE = 5.93% (Net Income TTM 2.31b / Total Stockholder Equity 39.0b)
RoCE = 7.48% (EBIT 3.43b / Capital Employed (Equity 39.0b + L.T.Debt 6.81b))
RoIC = 4.86% (NOPAT 2.62b / Invested Capital 54.0b)
WACC = 6.02% (E(79.9b)/V(97.8b) * Re(7.07%) + D(18.0b)/V(97.8b) * Rd(1.75%) * (1-Tc(0.24)))
Discount Rate = 7.07% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.39 | Cagr: 2.48%
[DCF] Terminal Value 76.92% ; FCFF base≈3.60b ; Y1≈3.98b ; Y5≈5.12b
[DCF] Fair Price = 138.5 (EV 78.2b - Net Debt 14.4b = Equity 63.7b / Shares 460.2m; r=8.35% [WACC [floored]]; 5y FCF grow 12.35% → 2.50% )
EPS Correlation: -54.48 | EPS CAGR: -0.99% | SUE: 0.0 | # QB: 0
Revenue Correlation: 96.07 | Revenue CAGR: 4.80% | SUE: 0.09 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=7.32 | Chg30d=-0.71% | Revisions=-25% | GrowthEPS=+7.7% | GrowthRev=+8.3%
EPS next Year (2027-12-31): EPS=8.32 | Chg30d=-1.52% | Revisions=+0% | GrowthEPS=+13.6% | GrowthRev=+10.3%
[Analyst] Revisions Ratio: -25%